Last €31.77 EUR
Change Today +0.201 / 0.64%
Volume 400.0
IM5 On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 2:05 PM 11/27/14 All times are local (Market data is delayed by at least 15 minutes).

alere inc (IM5) Snapshot

Open
€31.50
Previous Close
€31.57
Day High
€32.58
Day Low
€31.50
52 Week High
11/27/14 - €32.58
52 Week Low
04/30/14 - €23.41
Market Cap
2.7B
Average Volume 10 Days
43.2
EPS TTM
--
Shares Outstanding
83.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALERE INC (IM5)

alere inc (IM5) Related Businessweek News

View More BusinessWeek News

alere inc (IM5) Details

Alere Inc. provides point-of-care diagnostics and services for cardiology, infectious disease, toxicology, and diabetes in the United States and internationally. Its Professional Diagnostics segment provides diagnostic test products and other in vitro diagnostic tests to medical professionals and laboratories for detection of diseases and conditions in the areas of cardiology, infectious diseases, toxicology, diabetes, oncology, and women’s health, as well as offers connected device technologies. The company’s Health Information Solutions segment offers integrated programs and services focused on wellness, disease and condition management, productivity enhancement, and informatics. This segment’s health improvement programs comprise patient self-testing, condition and case management, women’s and children’s health, and health and wellness programs. Its Consumer Diagnostics segment provides products for over-the-counter pregnancy and fertility/ovulation test markets; and over-the-counter drug tests for at-home testing and cholesterol monitoring under the First Check brand name, as well as vaginal gel for the treatment of bacterial vaginosis without antibiotics. Alere Inc. markets its professional diagnostic products to hospitals, reference laboratories, physician offices, and other point-of-care settings through its sales force and distribution networks; health information solutions primarily to commercial and governmental health plans, self-insured employers, government and governmental programs, pharmaceutical companies, and physicians through sales force and channel partners; and First Check consumer drug testing products through retail drug stores, drug wholesalers, groceries, and mass merchandisers. The company was formerly known as Inverness Medical Innovations, Inc. and changed its name to Alere Inc. in July 2010. Alere Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

17,600 Employees
Last Reported Date: 03/3/14
Founded in 1981

alere inc (IM5) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Financial Officer, Vice President and T...
Total Annual Compensation: $408.8K
Compensation as of Fiscal Year 2013.

alere inc (IM5) Key Developments

Alere Inc. Reports Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Alere Inc. reported consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net revenue of $736,246,000 compared to $753,320,000 a year ago. Operating income was $37,612,000 compared to $25,584,000 a year ago. Loss from continuing operations before income taxes was $23,129,000 compared to $36,704,000 a year ago. Loss from continuing operations was $93,500,000 or $1.19 per basic and diluted share compared to $15,971,000 or $0.27 per basic and diluted share a year ago. Net loss available to common stockholders was $91,516,000 or $1.10 per basic and diluted share compared to $24,815,000 or $0.30 per basic and diluted share a year ago. Non-GAAP adjusted operating income was $126,343,000 compared to $136,529,000 a year ago. Non-GAAP adjusted net income available to common stockholders was $37,909,000 or $0.44 per diluted share compared to $50,070,000 or $0.59 per diluted share a year ago. Non-GAAP adjusted net income per diluted common share from continuing operations was $0.48 compared to $0.61 a year ago. Free cash flow for the third quarter of 2014 was a $62.9 million. Capital expenditures were $28.8 million. EBITDA for the third quarter of 2014 was $129.4 million. For the nine months, the company reported net revenue of $2,189,824,000 compared to $2,255,333,000 a year ago. Operating income was $62,749,000 compared to $109,215,000 a year ago. Loss from continuing operations before income taxes was $94,815,000 compared to $102,317,000 a year ago. Loss from continuing operations was $144,208,000 or $1.93 per basic and diluted share compared to $58,720,000 or $0.92 per basic and diluted share a year ago. Net loss available to common stockholders was $157,951,000 or $1.91 per basic and diluted share compared to $83,493,000 or $1.03 per basic and diluted share a year ago. Non-GAAP adjusted operating income was $350,924,000 compared to $414,826,000 a year ago. Non-GAAP adjusted net income available to common stockholders was $118,808,000 or $1.39 per diluted share compared to $148,663,000 or $1.75 per diluted share a year ago. Non-GAAP adjusted net income per diluted common share from continuing operations was $1.49 compared to $1.81 a year ago.

Alere Inc. Appoints Namal Nawana as Chief Executive Officer, President, and Member of the Board of Directors

Alere Inc. announced that Namal Nawana has been named Chief Executive Officer, President, and a Member of the Board of Directors of Alere. Nawana joined Alere in December 2012 as Chief Operating Officer and was appointed Interim Chief Executive Officer and President of Alere in July 2014. Before joining Alere, Nawana held various global leadership roles over the course of his 15-year tenure at Johnson & Johnson. He most recently served as Worldwide President of DePuy Synthes Spine, a Johnson & Johnson company.

Alere Inc. to Report Q3, 2014 Results on Oct 28, 2014

Alere Inc. announced that they will report Q3, 2014 results at 8:30 AM, US Eastern Standard Time on Oct 28, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IM5:GR €31.77 EUR +0.201

IM5 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $118.31 USD -0.64
BioMerieux €85.85 EUR +0.55
Getinge AB kr172.00 SEK -3.30
Steelcase Inc $17.75 USD +0.03
STERIS Corp $63.21 USD +0.70
View Industry Companies
 

Industry Analysis

IM5

Industry Average

Valuation IM5 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALERE INC, please visit www.alere.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.